TBIO vs. OMIC, AXDX, TLIS, ASTC, HLTH, PRPO, HTGMQ, SGMO, ADVM, and CGEN
Should you be buying Telesis Bio stock or one of its competitors? The main competitors of Telesis Bio include Singular Genomics Systems (OMIC), Accelerate Diagnostics (AXDX), Talis Biomedical (TLIS), Astrotech (ASTC), Cue Health (HLTH), Precipio (PRPO), HTG Molecular Diagnostics (HTGMQ), Sangamo Therapeutics (SGMO), Adverum Biotechnologies (ADVM), and Compugen (CGEN).
Telesis Bio (NASDAQ:TBIO) and Singular Genomics Systems (NASDAQ:OMIC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, community ranking, dividends, profitability and media sentiment.
Singular Genomics Systems has a consensus price target of $0.63, indicating a potential upside of 95.25%. Given Singular Genomics Systems' higher probable upside, analysts plainly believe Singular Genomics Systems is more favorable than Telesis Bio.
Telesis Bio has higher revenue and earnings than Singular Genomics Systems. Singular Genomics Systems is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.
Telesis Bio has a net margin of -183.66% compared to Singular Genomics Systems' net margin of -3,863.90%. Singular Genomics Systems' return on equity of -51.10% beat Telesis Bio's return on equity.
Singular Genomics Systems received 4 more outperform votes than Telesis Bio when rated by MarketBeat users. However, 52.94% of users gave Telesis Bio an outperform vote while only 46.43% of users gave Singular Genomics Systems an outperform vote.
Telesis Bio has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, Singular Genomics Systems has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
37.6% of Telesis Bio shares are held by institutional investors. Comparatively, 65.8% of Singular Genomics Systems shares are held by institutional investors. 24.5% of Telesis Bio shares are held by insiders. Comparatively, 22.2% of Singular Genomics Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Telesis Bio's average media sentiment score of 0.00 equaled Singular Genomics Systems'average media sentiment score.
Summary
Telesis Bio and Singular Genomics Systems tied by winning 7 of the 14 factors compared between the two stocks.
Get Telesis Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Telesis Bio Competitors List
Related Companies and Tools
